In the trial, 20% of patients didn’t respond well to the PCSK9 inhibitor—could genetic markers be used to tailor therapy?

Safety. Both evolocumab and alirocumab have been reported to be safe and well tolerated, with no report of causing hepatic transaminase elevation or hepatotoxicity. Nonserious injection site ...